Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-771 in Japanese Subjects With PID
NCT05150340Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Human normal immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Takeda. Started Jan 2022; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT05150340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150340.